Anxious Wait: UK Drugmakers in Limbo Over 100% Tariff Threat

A period of anxious waiting has begun for the UK’s pharmaceutical industry as it remains in limbo over Donald Trump’s threat to impose a devastating 100% tariff on its products. With the October 1st deadline approaching, drugmakers are looking to the government for a diplomatic breakthrough that could save them from being priced out of their largest export market.
The anxiety stems from the sector’s exclusion from a major US tariff deal negotiated five months ago. That agreement, which covered other key industries, has left pharmaceutical companies like GSK completely exposed. A government spokesperson confirmed they are aware of the industry’s concern and are actively engaging with Washington, but has offered no concrete assurances of a successful outcome.
The tariff threat has overshadowed recent attempts to strengthen US-UK ties. A state visit for Trump, featuring a banquet at Windsor Castle attended by industry leaders, failed to produce any tangible protection for the sector. A previous promise from Trump himself to give UK pharma “preferential treatment” has also been cast aside, adding to the sense of betrayal and uncertainty.
Some market observers have offered a sliver of hope, suggesting the tariffs are a strategic measure aimed at companies that don’t manufacture in the US. This “bark versus bite” theory posits that firms with American factories will be safe. This is backed by statements from several European giants, including Novartis and Roche, who expect their US investments to shield them from the duties.
This potential exemption, however, does little to calm the nerves of companies without a US footprint or other European sectors caught in the crossfire. German truck makers are furious about a separate 25% tariff, and the EU is worried that a US investigation into medical devices could signal the next wave of trade restrictions, ensuring that the climate of uncertainty will persist.